AAA86662.1
[Other Products]
UniProt Primary Accession #
|
[Other Products]
UniProt Secondary Accession #
UniProt Related Accession #
NCBI Official Full Name
ubiquitin-conjugating enzyme
NCBI Official Synonym Full Names
ubiquitin-conjugating enzyme E2I
NCBI Protein Information
SUMO-conjugating enzyme UBC9; SUMO-protein ligase; SUMO-1-protein ligase; ubiquitin-protein ligase I; ubiquitin carrier protein 9; ubiquitin carrier protein I; ubiquitin-protein ligase E2I; ubiquitin conjugating enzyme 9; ubiquitin-conjugating enzyme UbcE2A; ubiquitin-like protein SUMO-1 conjugating enzyme; ubiquitin-conjugating enzyme E2I (UBC9 homolog, yeast); ubiquitin-conjugating enzyme E2I (homologous to yeast UBC9)
UniProt Protein Name
SUMO-conjugating enzyme UBC9
UniProt Synonym Protein Names
SUMO-protein ligase; Ubiquitin carrier protein 9; Ubiquitin carrier protein I; Ubiquitin-conjugating enzyme E2 I; Ubiquitin-protein ligase I; p18
UniProt Synonym Gene Names
UniProt Entry Name
UBC9_HUMAN
NCBI Summary for UBE2I
The modification of proteins with ubiquitin is an important cellular mechanism for targeting abnormal or short-lived proteins for degradation. Ubiquitination involves at least three classes of enzymes: ubiquitin-activating enzymes, or E1s, ubiquitin-conjugating enzymes, or E2s, and ubiquitin-protein ligases, or E3s. This gene encodes a member of the E2 ubiquitin-conjugating enzyme family. Four alternatively spliced transcript variants encoding the same protein have been found for this gene. [provided by RefSeq, Jul 2008]
UniProt Comments for UBE2I
Function: Accepts the ubiquitin-like proteins SUMO1, SUMO2, SUMO3 and SUMO4 from the UBLE1A-UBLE1B E1 complex and catalyzes their covalent attachment to other proteins with the help of an E3 ligase such as RANBP2 or CBX4. Can catalyze the formation of poly-SUMO chains. Necessary for sumoylation of FOXL2 and KAT5. Essential for nuclear architecture and chromosome segregation. Sumoylates p53/TP53 at 'Lys-386'. Ref.1 Ref.20 Ref.25 Ref.35 Ref.36 Ref.47 Ref.48
Catalytic activity: ATP + SUMO + protein lysine = AMP + diphosphate + protein N-SUMOyllysine.
Pathway: Protein modification; protein sumoylation.
Subunit structure: Interacts with HIPK1, HIPK2, PPM1J, RASD2 and TCF3 Interacts with NR2C1; the interaction promotes its sumoylation
By similarity. Forms a tight complex with RANGAP1 and RANBP2. Interacts with SIAH1 and PARP. Interacts with various transcription factors such as TFAP2A, TFAP2B, TFAP2C, AR, ETS1 and SOX4. Interacts with RWDD3; the interaction enhances the sumoylation of a number of proteins such as HIF1A and I-kappa-B. Interacts with DNMT1. Interacts with FOXL2. Forms a complex with SENP6 and UBE2I in response to UV irradiation. Interacts with human herpesvirus 6 IE2. Interacts with human adenovirus early E1A protein; this interaction interferes with polysumoylation
Probable. Interacts with DNM1l (via its GTPase and B domains); the interaction promotes sumoylation of DNM1L, mainly in its B domain. Interacts with PML-RARA oncoprotein (via the coiled-colied domain); the interaction is required for sumoylation of the PML-RARA oncoprotein. Interacts with IPO13. Interacts with NFATC2IP; this inhibits formation of poly-SUMO chains. Interacts with FHIT. Interacts with PRKRA and p53/TP53
By similarity. Interacts with UHRF2. Ref.4 Ref.16 Ref.17 Ref.18 Ref.19 Ref.21 Ref.23 Ref.24 Ref.25 Ref.26 Ref.28 Ref.29 Ref.30 Ref.34 Ref.35 Ref.36 Ref.38 Ref.42 Ref.47 Ref.48
Subcellular location: Nucleus. Cytoplasm. Note: Mainly nuclear. In spermatocytes, localizes in synaptonemal complexes. Recruited by BCL11A into the nuclear body
By similarity. Ref.28 Ref.35 Ref.40
Tissue specificity: Expressed in heart, skeletal muscle, pancreas, kidney, liver, lung, placenta and brain. Also expressed in testis and thymus. Ref.5
Post-translational modification: Phosphorylation at Ser-71 significantly enhances SUMOylation activity.
Sequence similarities: Belongs to the ubiquitin-conjugating enzyme family.
Sequence caution: The sequence AAH51289.3 differs from that shown. Reason: Erroneous initiation. Translation N-terminally shortened.The sequence BAD92225.1 differs from that shown. Reason: Erroneous initiation. Translation N-terminally shortened.
Research Articles on UBE2I
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice. It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Products associated with UBE2I peptide
Pathways associated with UBE2I peptide
Diseases associated with UBE2I peptide
Organs/Tissues associated with UBE2I peptide
|